http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2030917-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_884ad63d037bdd844858631b34832703 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 |
| filingDate | 1991-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1995-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fda43f396d3cf8b248ac99d00ff198ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_156c6146fbb88df5c99d1341af5230cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8cd86ef29a280b7d4115ebfc7b68736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff438d4fe41529c578ac68936a77e675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eb6b12dabd9872dbefeaa19dba6d081 |
| publicationDate | 1995-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2030917-C1 |
| titleOfInvention | Vaccine for plague, infection hepatitis, adenoviral infections and parvoviral enteritis prophylaxis in dogs, and a method of prophylaxis of plague, infection hepatitis, adenoviral infections and parvoviral enteritis in dogs |
| abstract | FIELD: veterinary virology. SUBSTANCE: vaccine contains inactivated viral suspension of canine adenovirus 2 serotype "Ada" strain with infection activity titer 10 4,5 -10 5,0 ТЦД 50/cm 3, inactivated viral suspension of feline pandeicopenia "Hannibal" strain with infection activity titer 10 4,0 -10 5,0 ИД 50/cm 3 and hemagglutinating activity 1:64-256 ГАЕ/ cm 3, viral material of strain ЭПМ with infection activity titer 10 3,0 -10 4,0 ТЦД 50/0,5cm 3, aluminium hydroxide, sorbitol-gelatinous stabilizing agent, distilled water and Henx solution. Formalin is used for viruses inactivation, and sodium metabisulfate is used for their neutralization. Preparation is administrated to dogs by intracutaneous or intramuscular injections once, and to puppies - twofold with interval 7-10 days at the dose 1-2 cm 3 . EFFECT: increased effectiveness of vaccine. 3 cl, 3 tbl |
| priorityDate | 1991-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.